Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.63 |
| ▸ | MGLL | Q99685 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | CASP6 | P55212 | 1/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.50 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30475446 | 0.92 | L3MBTL1 (0.86) | L3MBTL1HSP90AA1MGLLMAPTHSD17B10 | |
| SCHEMBL29749910 | 0.85 | L3MBTL1 (0.73) | L3MBTL1MGLLMAPTHSD17B10KMT2A | |
| SCHEMBL8121918 | 0.81 | L3MBTL1 (0.68) | L3MBTL1HSP90AA1MGLLMAPTHSD17B10 | |
| SCHEMBL29702887 | 0.81 | L3MBTL1 (0.68) | L3MBTL1HSP90AA1MGLLMAPTHSD17B10 | |
| SCHEMBL13284168 | 0.80 | L3MBTL1 (0.67) | L3MBTL1HSP90AA1MGLLMAPTHSD17B10 | |
| SCHEMBL11121830 | 0.80 | L3MBTL1 (0.66) | L3MBTL1HSP90AA1MGLLMAPTHSD17B10 | |
| SCHEMBL11842431 | 0.78 | L3MBTL1 (0.64) | L3MBTL1HSP90AA1MGLLMAPTHSD17B10 | |
| SCHEMBL11466089 | 0.78 | HSP90AA1 (0.66) | L3MBTL1HSP90AA1MGLLMAPTHSD17B10 | |
| SCHEMBL3791105 | 0.78 | KMT2A (0.66) | L3MBTL1HSP90AA1MGLLMAPTKMT2A | |
| SCHEMBL139864 | 0.78 | MGLL (1.00) | L3MBTL1HSP90AA1MGLLMAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2480529-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | F. Hoffmann-La Roche AG (CH) | 2012-08-01 | — | — | EP | claimed |
| WO-2011036130-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | claimed |
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ALAM MUZAFFAR | 2011-03-24 | — | — | US | claimed |
| WO-2024050825-A1 | COMPOUNDS AS MLKL INHIBITORS | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2024-03-14 | — | — | WO | disclosed |
| EP-2480529-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | F. Hoffmann-La Roche AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| US-8067586-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2011-11-29 | — | — | US | disclosed |
| US-8067586-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2011-11-29 | — | — | US | disclosed |
| WO-2011036130-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | disclosed |
| EP-1277738-B1 | CONDENSED HETEROARYL DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2011-03-30 | — | — | EP | disclosed |
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ALAM MUZAFFAR | 2011-03-24 | — | — | US | disclosed |
| US-20100137584-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20100137585-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20100137584-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20100137585-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20070037805-A1 | Fused heteroaryl derivatives | HAYAKAWA MASAHIKO | 2007-02-15 | — | — | US | disclosed |
| US-20070037805-A1 | Fused heteroaryl derivatives | HAYAKAWA MASAHIKO | 2007-02-15 | — | — | US | disclosed |
| US-7173029-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-06 | — | — | US | disclosed |
| US-7173029-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137584-A1 | FUSED HETEROARYL DERIVATIVES | PIK3CD, PIK3R3, PIK3C2A | L3MBTL1 3535/4885HSP90AA1 1825/4885MGLL 3130/4885 |
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ORAI1, RYR2, CACNA1E | L3MBTL1 4396/4885HSP90AA1 3424/4885MGLL 2664/4885 |
| US-20070037805-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | L3MBTL1 3535/4885HSP90AA1 1825/4885MGLL 3130/4885 |
| US-20100137585-A1 | FUSED HETEROARYL DERIVATIVES | PIK3CD, PIK3R3, PIK3C2A | L3MBTL1 3535/4885HSP90AA1 1825/4885MGLL 3130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.